Table 1.
Baseline demographics and clinical characteristics.
| Stereotactic Body Radiotherapy Group (n = 414) |
Conventional Fractionated or Moderately Hypofractionated Radiotherapy (n = 428) |
|
|---|---|---|
| Median age in years | 69 (65–73) | 69 (65–73) |
| NCCN risk group | ||
| low | 35 (8%) | 43 (10%) |
| intermediate | 379 (92%) | 885 (90%) |
| Performance status | ||
| 0 | 372 (90%) | 379 (88.5%) |
| 1 | 42 (10%) | 47 (11%) |
| 2 | - | 2 (0.5%) |
| Gleason Score | ||
| 3 + 3 | 61 (15%) | 84 (20%) |
| 3 + 4 | 353 (85%) | 344 (80%) |
| Median pre-randomisation PSA |
8 (5.5–11) | 8 (6.3–10.7) |
| Prostate volume | ||
| <40ml | 189 (45%) | 163 (38%) |
| 40–80ml | 197 (48%) | 223 (52%) |
| 80ml + | 23 (6%) | 27 (6%) |
| Missing | 5 | 15 |
| Pre-randomisation use of Alpha-blocker | ||
| Yes | 77 (19%) | 84 (20%) |
| No | 337 (81%) | 344 (80%) |
| Pre-randomisation use of anti-cholinergic | ||
| Yes | 17 (4%) | 15 (4%) |
| No | 397 (96%) | 413 (96%) |
| Fiducial marker use | ||
| Yes | 303 (73.2%) | 244 (57%) |
| No | 111 (26.8%) | 184 (43%) |
| SBRT technique | ||
| Conventional linac (CL) | 242 (58.5%) | - |
| CyberKnife | 169 (40.8%) | - |
| Other | 3 (0.7%) | - |
Data is presented in median (IQR), n (%). NCCN = National comprehensive cancer network. PSA = prostate-specific antigen. SBRT = Stereotactic body radiotherapy.